Literature DB >> 10469436

Cognitive impairment in neurofibromatosis type 1.

S Ozonoff1.   

Abstract

Neurofibromatosis type 1 (NF1) is associated with a broad range of relatively nonspecific cognitive impairments, including low IQ, learning disabilities, and behavioral difficulties. While early studies indicated that the cognitive phenotype of NF1 resembles that of nonverbal learning disabilities (NLD), later research has found that the impairments are broader and do not fit the NLD profile well. Language-based deficits and executive dysfunction have also been found in empirical studies. There is some evidence that neuropsychological impairment may be correlated with the underlying central nervous system involvement of NF1, but this theory has not been consistently supported across studies. Further work clarifying the cognitive phenotype of NF1 is needed, especially investigations that employ appropriate comparison groups matched for intellectual level. Am. J. Med. Genet. (Semin. Med. Genet.) 89:45-52, 1999. Copyright 1999 Wiley Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10469436

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  46 in total

Review 1.  Genetic effects on human cognition: lessons from the study of mental retardation syndromes.

Authors:  P Nokelainen; J Flint
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-03       Impact factor: 10.154

Review 2.  Small G protein signaling in neuronal plasticity and memory formation: the specific role of ras family proteins.

Authors:  Xiaojing Ye; Thomas J Carew
Journal:  Neuron       Date:  2010-11-04       Impact factor: 17.173

Review 3.  Neural phenotypes of common and rare genetic variants.

Authors:  Carrie E Bearden; David C Glahn; Agatha D Lee; Ming-Chang Chiang; Theo G M van Erp; Tyrone D Cannon; Allan L Reiss; Arthur W Toga; Paul M Thompson
Journal:  Biol Psychol       Date:  2008-02-23       Impact factor: 3.251

Review 4.  Sensitization of Ion Channels Contributes to Central and Peripheral Dysfunction in Neurofibromatosis Type 1.

Authors:  Aubin Moutal; Erik T Dustrude; Rajesh Khanna
Journal:  Mol Neurobiol       Date:  2016-05-11       Impact factor: 5.590

5.  MR imaging of the corpus callosum in pediatric patients with neurofibromatosis type 1.

Authors:  E C Dubovsky; T N Booth; G Vezina; C A Samango-Sprouse; K M Palmer; C O Brasseux
Journal:  AJNR Am J Neuroradiol       Date:  2001-01       Impact factor: 3.825

6.  Pain, skin sensations symptoms, and cognitive functioning predictors of health-related quality of life in pediatric patients with Neurofibromatosis Type 1.

Authors:  James W Varni; Kavitha Nutakki; Nancy L Swigonski
Journal:  Qual Life Res       Date:  2018-11-21       Impact factor: 4.147

7.  HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.

Authors:  A Omrani; T van der Vaart; E Mientjes; G M van Woerden; M R Hojjati; K W Li; D H Gutmann; C N Levelt; A B Smit; A J Silva; S A Kushner; Y Elgersma
Journal:  Mol Psychiatry       Date:  2015-04-28       Impact factor: 15.992

8.  Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention.

Authors:  Karin S Walsh; Jennifer Janusz; Pamela L Wolters; Staci Martin; Bonita P Klein-Tasman; Mary Anne Toledo-Tamula; Heather L Thompson; Jonathan M Payne; Kristina K Hardy; Peter de Blank; Claire Semerjian; Laura Schaffner Gray; Sondra E Solomon; Nicole Ullrich
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

9.  The RAS effector RIN1 modulates the formation of aversive memories.

Authors:  Ajay Dhaka; Rui M Costa; Hailiang Hu; Dwain K Irvin; Apoor Patel; Harley I Kornblum; Alcino J Silva; Thomas J O'Dell; John Colicelli
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

10.  Brief Report: The Prevalence of Neurofibromatosis Type 1 among Children with Autism Spectrum Disorder Identified by the Autism and Developmental Disabilities Monitoring Network.

Authors:  Deborah A Bilder; Amanda V Bakian; David A Stevenson; Paul S Carbone; Christopher Cunniff; Alyson B Goodman; William M McMahon; Nicole P Fisher; David Viskochil
Journal:  J Autism Dev Disord       Date:  2016-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.